Single Vaccine Dose is Sufficient For Recovered Covid Patients, Reveals ICMR Study
According to a new study by the Indian Council of Medical Research (ICMR), citizens who have recovered from Covid-19 and received one or both doses of vaccine exhibit a higher level of protection against the Delta variant as compared to people who have taken one or two doses of Covishield.
The study shows that cellular and humoral immune response plays an important role in protection against the Delta variant of the Covid-19, which is highly transmissible than other mutated waves.
The ICMR report mentioned that, “The findings of the study demonstrated that the breakthrough cases and the Covid-19 recovered individuals with one or two-dose of vaccine had relatively higher protection against Delta variant in comparison to the participants who were administered either one or two doses of Covishield. Prior vaccination results in less severe disease against subsequent infection provide evidence that both humoral and cellular immune response plays an important role in protection.”
Researches show that only one dose of vaccine in a Covid-recovered patient is enough to shield against a coronavirus re-infection and gives more protection against newly emerging variants because they carry naturally high neutralizing antibody count. The neutralizing antibodies in advance cases and Covid-recovered patients with one or two doses of vaccine will have comparable higher safety against Delta variant in front of the people who were administered either one or two doses of Covishield.
An employee removes vials of Covishield, the local name for the Covid-19 vaccine developed by AstraZeneca Plc. and the University of Oxford, from a machine on the production line at the Serum Institute of India Ltd. Hadaspar plant in Pune, Maharashtra, India, on Friday, Jan. 22, 2021. Serum, which is the world’s largest vaccine maker by volume, has an agreement with AstraZeneca to produce at least a billion doses. Photographer: Dhiraj Singh/Bloomberg via Getty Images
It further added, “Long-term follow-up of participants could help understand the impact of natural infection and vaccination on long-term protection from SARS-CoV-2 offered by Covishield. It is important to track the breakthrough infections to look for unexpected changes.”
The study believes that currently available vaccines produce robust humoral and cellular immune responses against coronavirus. “Monitoring of breakthrough infection would make us understand the impact of new variant or VOC on the escape of vaccine-induced immunity. Data has shown again and again that if the individuals get infected post-vaccination, had been protected from severe disease,” said the study.
